Defining Speech Subtypes in De Novo Parkinson Disease: Response to Long-term Levodopa Therapy. Rusz J, Tykalova T, Novotny M, Zogala D, et al. Neurology 2021 Oct 4. pii: WNL.0000000000012878.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Rusz J, Tykalova T, Novotny M, Zogala D, et al. Defining Speech Subtypes in De Novo Parkinson Disease: Response to Long-term Levodopa Therapy. Neurology 2021 Oct 4. pii: WNL.0000000000012878.
PMID: 34607922